Kanchan Rao1, Stuart Adams2, Waseem Qasim3, Zoe Allwood2, Austen Worth3, Juliana Silva2, Giovanna Lucchini2, Robert Chiesa2, Paul Veys2, Persis Amrolia3. 1. Department of Blood and Marrow Transplantation, Great Ormond Street Hospital for Children, London, United Kingdom. Electronic address: kanchan.rao@gosh.nhs.uk. 2. Department of Blood and Marrow Transplantation, Great Ormond Street Hospital for Children, London, United Kingdom. 3. Department of Blood and Marrow Transplantation, Great Ormond Street Hospital for Children, London, United Kingdom; Molecular Immunology Unit, Institute of Child Health, University College London, London, United Kingdom.
Abstract
BACKGROUND: Reduced-intensity conditioning (RIC) regimens are increasingly being used in the transplantation of patients with primary immunodeficiency disorders (PIDs), but there are no large studies looking at long-term lineage-specific chimerism. OBJECTIVES: We sought to analyze long-term chimerism and event-free survival in children undergoing transplantation for PIDs using RIC with fludarabine and melphalan (Flu/Melph) and to study the effect of donor type and stem cell source. METHODS: One hundred forty-two children underwent transplantation with RIC by using Flu/Melph and for PIDs by using bone marrow (n = 93) or peripheral blood stem cells (PBSCs; n = 49). Donors were matched unrelated donors (n = 72), mismatched unrelated donors (n = 37), matched sibling donors (n = 14), matched family donors (n = 12), and mismatched family donors (n = 7). RESULTS: Overall survival at a median follow-up of 7.5 years was 78%, irrespective of stem cell source or donor type. When bone marrow was used as the stem cell source, 26% of patients ended up with very low levels of donor chimerism (<10% donor), especially in the myeloid lineage. Event-free survival in this group was significantly lower compared with that in the rest of the group (25% vs 70%, P < .001). With the use of PBSCs, more than 90% of patients achieved complete donor chimerism or high-level mixed chimerism (>50% donor chimerism) in all lineages. CONCLUSIONS: On the basis of our experience, we would suggest that PBSCs should be the stem cell source of choice in children with PIDs undergoing transplantation with Flu/Melph RIC from a matched donor source. This is most likely to ensure sustained high-level donor chimerism.
BACKGROUND: Reduced-intensity conditioning (RIC) regimens are increasingly being used in the transplantation of patients with primary immunodeficiency disorders (PIDs), but there are no large studies looking at long-term lineage-specific chimerism. OBJECTIVES: We sought to analyze long-term chimerism and event-free survival in children undergoing transplantation for PIDs using RIC with fludarabine and melphalan (Flu/Melph) and to study the effect of donor type and stem cell source. METHODS: One hundred forty-two children underwent transplantation with RIC by using Flu/Melph and for PIDs by using bone marrow (n = 93) or peripheral blood stem cells (PBSCs; n = 49). Donors were matched unrelated donors (n = 72), mismatched unrelated donors (n = 37), matched sibling donors (n = 14), matched family donors (n = 12), and mismatched family donors (n = 7). RESULTS: Overall survival at a median follow-up of 7.5 years was 78%, irrespective of stem cell source or donor type. When bone marrow was used as the stem cell source, 26% of patients ended up with very low levels of donor chimerism (<10% donor), especially in the myeloid lineage. Event-free survival in this group was significantly lower compared with that in the rest of the group (25% vs 70%, P < .001). With the use of PBSCs, more than 90% of patients achieved complete donor chimerism or high-level mixed chimerism (>50% donor chimerism) in all lineages. CONCLUSIONS: On the basis of our experience, we would suggest that PBSCs should be the stem cell source of choice in children with PIDs undergoing transplantation with Flu/Melph RIC from a matched donor source. This is most likely to ensure sustained high-level donor chimerism.
Authors: Kanwaldeep K Mallhi; Meera A Srikanthan; Kelsey K Baker; Haydar A Frangoul; Troy R Torgerson; Aleksandra Petrovic; Amy E Geddis; Paul A Carpenter; K Scott Baker; Brenda M Sandmaier; Monica S Thakar; Suzanne Skoda-Smith; Hans-Peter Kiem; Rainer Storb; Ann E Woolfrey; Lauri M Burroughs Journal: Biol Blood Marrow Transplant Date: 2020-03-28 Impact factor: 5.742
Authors: Sharat Chandra; Shanmuganathan Chandrakasan; Pooja Khandelwal; Rebecca A Marsh; Blachy J Dávila Saldaña; Jack J Bleesing; Michael B Jordan; Ashish R Kumar; Michael S Grimley; Christa Krupski; Stella M Davies Journal: J Clin Immunol Date: 2020-10-16 Impact factor: 8.317
Authors: Young Bae Choi; Ji Won Lee; Ki Woong Sung; Hong Hoe Koo; Hee-Jin Kim; Keon Hee Yoo Journal: J Korean Med Sci Date: 2019-01-29 Impact factor: 2.153